Important new data from Eli Lilly and Company on the effectiveness of its tirzepatide in weight loss looks promising, but the company still faces an uphill climb to get physicians and insurers to embrace the treatment as an important tool in disease prevention.
In early Phase 3 results, the drug achieved an average 22.5% weight loss in patients without diabetes who were enrolled...







